Osteochondral Autograft (OATS/Mosaicplasty)

July 2026: an international consensus names this the primary option for cystic, uncontained and revision lesions

→ This is the closest thing to a direct answer that exists for this specific lesion — but it is expert opinion, not a trial.

A 106-author Delphi consensus from the International Congress on Cartilage Repair of the Ankle, published July 29, 2026, addresses talar lesions of 1–2.9 cm² — the band a 15 × 10 mm lesion (~1.5 cm²) falls in [247]. Its central statement is that autologous osteochondral transplantation is supported as a primary treatment option for cystic, uncontained and revision lesions, with emphasis on graft continuity and appropriate depth. All three of those qualifiers describe this case at once, which no other document recorded on this page does.

The consensus also holds that scaffold-based techniques, while viable in select primary and revision settings, are not superior to autograft for larger lesions, and that osteochondral allograft is the choice for larger or uncontained lesions and where autograft is contraindicated — with a preference for fresh, size-matched grafts used within 28 days.

What it is worth. It is Level V expert consensus, and the authors state directly that the underlying literature “remains heterogeneous with limited high-level evidence.” It reorders a preference list rather than proving a winner, and it should not be read as outcome data. Two honest limits on this entry: the full text could not be retrieved (the publisher blocks automated access and the paper is not yet indexed), so the individual statements and their percentage agreement are unread; and it must be weighed against the ten-year randomized ACTIVE trial recorded in the July 29 research log, which found cell therapy held up well in a revision population. Read together, the fair conclusion is that autograft and cell-based repair are both defensible for a revision cystic talar lesion, and the comparative trial that would separate them in the ankle has not been run.

Long-Term Outcomes (10+ Years)

→ OATS takes a plug of healthy cartilage+bone from your knee and presses it into the ankle defect like a cork in a bottle. Your own tissue = no rejection risk. Downside: creates a new wound in your knee.

Systematic review with 10.2 year mean follow-up (610 patients, 10 studies) [35]:

• Overall success rate: 72% at long-term follow-up [35]
• Mean AOFAS improved from 60.4 to 86.2 at minimum 10-year follow-up [36]
• VAS decreased from 6.3 to 2.0 [36]
• Results do not deteriorate over time [37]

2024 Systematic Review Update

A 2024 systematic review in JOSR evaluated OATS outcomes [75]:

• OATS remains the gold standard for large cystic OLT (>150 mm²)
• Return to sport rate: 76-83% at 2-year follow-up
• Superior to BMS for lesions >1.5 cm² with bone involvement

2024 Ten-Year AOT Review

A 2024 study with minimum 10-year follow-up reported strong long-term durability [151]:

• Mean lesion size: 122.3 mm², 43.6% cystic lesions, 28.2% had prior microfracture
• FAOS improved from 51.9 to 75.3, VAS from 6.6 to 1.6
• Only 2 failures (5.1%) — both had prior microfracture plus postoperative cysts
• 94.9% survival rate at minimum 10-year follow-up

2026 Multi-Plug AOT for Large Lesions

A 2026 series using multiple plugs for large OLTs [152]:

• No conversion to arthrodesis or arthroplasty in first year
• However, knee donor-site pain across reviews still ranges 6.7%-16.9%

Autograft vs Allograft (Meta-analysis of 1174 procedures)

Autografts significantly outperform allografts [38]:

→ Autograft = your own tissue; Allograft = donor tissue (like a transplant)

• Lower revision surgery rate: OR 7.2 (p<0.0001)
  → OR = Odds Ratio; 7.2 means allografts are 7.2x more likely to need revision surgery
• Lower failure rate: OR 5.1 (p<0.0001)

2024-2025 Updates on Surgical Technique

Recent advances in osteochondral autograft procedures [76]:

• Novel arthroscopic-assisted techniques reduce surgical morbidity
• CT/fluoroscopic navigation improves plug placement accuracy
• Single-plug technique preferred for lesions <15mm diameter [77]

Donor Site Morbidity (Major Concern)

→ Donor site morbidity = problems caused at the site where tissue was taken (the knee, in OATS procedures)

Systematic review of 1726 patients (21 studies) [39]:

→ MCP = mosaicplasty (multiple small plugs); DSM = donor site morbidity

2025 Donor Site Study

A 2025 study on predictors of donor site morbidity found [40]:

• Overall DSM rate: 9.8% using Lysholm Knee Score
• Higher BMI significantly correlated with increased morbidity
• Number of plugs harvested is key predictor

Ipsilateral Talus as Donor Site (2024)

Emerging technique using autologous ipsilateral talus grafts [78]:

→ Ipsilateral = same side; taking cartilage from another part of the SAME ankle instead of the knee

• Eliminates knee donor site morbidity entirely
• Comparable biomechanical properties to defect site
• Limited to smaller lesions due to available donor area

2026 Donor Site Selection Within the Knee (Finite Element Analysis)

→ If a plug is taken from the knee, where in the knee it comes from has never been standardised — surgeons largely pick by access and habit. This study is the first to compare the candidate spots by simulated mechanics.

Patient-specific finite element models were built from postoperative CT of 17 patients with cystic osteochondral lesions of the talus — the same lesion morphology as this one — and six femoral condyle donor regions were compared under a simulated standing load [226]:

• Stress and strain did not differ significantly between any of the six donor sites (p>0.05 after Bonferroni correction) — on those measures, the choice appears not to matter
• The medial superior region was the exception on displacement. Grafts from it moved significantly less than the mean of the talar articular surface (p=0.002) and significantly less than grafts from every other donor site (p<0.05)

How much weight to give this. Not much yet, but it is worth knowing. This is a computer simulation under a single static standing load, built from 17 models, with no clinical outcomes and no validation against real patient results. It cannot show that a medial superior plug lasts longer or hurts less. What it does is turn donor-site selection from a matter of surgeon habit into a question with at least one biomechanical argument attached — a reasonable thing to raise with a surgeon who is proposing autograft, not a reason to choose autograft.

Key issue: Patients receiving 2+ plug grafts have worse knee scores (96 vs 98, p<0.05). Knee and talus cartilage do not biomechanically match [39].